Trifluoroperazine

Trifluoroperazine (TFP) is the generic name for a clinically [cite journal|name="pmid14974020" | author="Marques, L O and Lima, M S and Soares, B G O" | title="Trifluoperazine for schizophrenia" | journal="Cochrane Database Syst Rev" | year="2004" | number="1" | pages="CD003545"] and experimentally [@Article{pmid16824931, Author="Ondarza, Raul N and Iturbe, Angelica and Hernandez, Eva", Title="{In vitro antiproliferative effects of neuroleptics, antimycotics and antibiotics on the human pathogens Acanthamoeba polyphaga and Naegleria fowleri}", Journal="Arch Med Res", Year="2006", Volume="37", Number="6", Pages="723--729", Month="Aug" }] [@Article{pmid7887964, Author="Ning, Y M and Sanchez, E R", Title="{Evidence for a functional interaction between calmodulin and the glucocorticoid receptor}", Journal="Biochem Biophys Res Commun", Year="1995", Volume="208", Number="1", Pages="48--54", Month="Mar" }] [@Article{pmid7700236, Author="Bouquin, N and Tempete, M and Holland, I B and Seror, S J", Title="{Resistance to trifluoroperazine, a calmodulin inhibitor, maps to the fabD locus in Escherichia coli}", Journal="Mol Gen Genet", Year="1995", Volume="246", Number="5", Pages="628--637", Month="Mar"}] useful drug.

It has been shown to be useful in relation to schizophrenia; it works as a calmodulin inhibitor.

References